2/24
09:00 am
adil
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement
Low
Report
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement
2/23
08:30 am
adil
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One
Medium
Report
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One
2/17
09:08 am
adil
Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Medium
Report
Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/17
09:00 am
adil
Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Medium
Report
Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
2/11
10:58 am
adil
Adial Pharmaceuticals (NASDAQ:ADIL) was given a new $8.00 price target on by analysts at UBS Group AG.
Medium
Report
Adial Pharmaceuticals (NASDAQ:ADIL) was given a new $8.00 price target on by analysts at UBS Group AG.
2/4
09:35 am
adil
Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04
Medium
Report
Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04
2/3
06:05 pm
adil
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement [Yahoo! Finance]
Medium
Report
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement [Yahoo! Finance]
2/3
04:05 pm
adil
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement
High
Report
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement
1/14
09:00 am
adil
Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045
Low
Report
Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045